Annual Report And Accounts

Overview

The report describes BerGenBio's successful 2017 IPO and Oslo Stock Exchange listing, alongside a broad clinical programme of six Phase II trials. It reports that the Group had 26 employees at year end and no operating revenues in 2017. The report also highlights continued development of bemcentinib across lung cancer, breast cancer, melanoma and AML/MDS indications.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2017
Period: 1 January 2017 – 31 December 2017
Publication date: 5 April 2018
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services